×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VCNX – vaccinex, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VCNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
08:35 am
vcnx
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/18
08:30 am
vcnx
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/7
08:30 am
vcnx
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Neutral
Report
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
11/5
08:30 am
vcnx
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Low
Report
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
10/31
10:00 am
vcnx
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
High
Report
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
10/24
08:30 am
vcnx
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
High
Report
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
10/16
05:04 pm
vcnx
Vaccinex files for secondary stock offering [Seeking Alpha]
Medium
Report
Vaccinex files for secondary stock offering [Seeking Alpha]
9/18
08:49 am
vcnx
Vaccinex exercises warrants for proceeds of $6.2M [Seeking Alpha]
Medium
Report
Vaccinex exercises warrants for proceeds of $6.2M [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
04:16 pm
vcnx
Form SC 13D/A VACCINEX, INC. Filed by: Zauderer Maurice
Medium
Report
Form SC 13D/A VACCINEX, INC. Filed by: Zauderer Maurice
11/18
04:07 pm
vcnx
Form 4 VACCINEX, INC. For: Nov 14 Filed by: FRIEDBERG ALBERT
Medium
Report
Form 4 VACCINEX, INC. For: Nov 14 Filed by: FRIEDBERG ALBERT
11/18
04:06 pm
vcnx
Form 4 VACCINEX, INC. For: Nov 14 Filed by: Zauderer Maurice
Medium
Report
Form 4 VACCINEX, INC. For: Nov 14 Filed by: Zauderer Maurice
11/14
05:01 pm
vcnx
Form 8-K VACCINEX, INC. For: Nov 13
High
Report
Form 8-K VACCINEX, INC. For: Nov 13
11/14
04:46 pm
vcnx
Form 10-Q VACCINEX, INC. For: Sep 30
High
Report
Form 10-Q VACCINEX, INC. For: Sep 30
11/14
03:40 pm
vcnx
Form SC 13G VACCINEX, INC. Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G VACCINEX, INC. Filed by: ARMISTICE CAPITAL, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/23
Form 8-K VACCINEX, INC. For: Jan 21
35.7%
3/14 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.00 price target on the stock. 19.7%
1/27 Form 4 VACCINEX, INC. For: Jan 23 Filed by: Zauderer Maurice 19.1%
11/12 Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update 12.0%
9/24 Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference 10.3%
8/1 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.9%
3/11 Form 4 VACCINEX, INC. For: Mar 09 Filed by: FRIEDBERG ALBERT 7.0%
9/13 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 6.5%
7/19 Form 8-K VACCINEX, INC. For: Jul 15 6.0%
12/12 Vaccinex Inc (NASDAQ: VCNX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.1%
3/14 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.00 price target on the stock. 19.7%
1/27 Form 4 VACCINEX, INC. For: Jan 23 Filed by: Zauderer Maurice 19.1%
11/12 Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update 12.0%
9/24 Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference 10.3%
8/1 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.9%
3/11 Form 4 VACCINEX, INC. For: Mar 09 Filed by: FRIEDBERG ALBERT 7.0%
9/13 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 6.5%
7/19 Form 8-K VACCINEX, INC. For: Jul 15 6.0%
12/12 Vaccinex Inc (NASDAQ: VCNX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.1%
TOP News Decliners
2/28
Vaccinex Inc (NASDAQ: VCNX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating.
-18.3%
11/9 Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) -11.1%
3/17 Vaccinex Inc (NASDAQ: VCNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.9%
3/23 Form 4 VACCINEX, INC. For: Mar 19 Filed by: FRIEDBERG ALBERT -9.4%
4/1 Form 4 VACCINEX, INC. For: Mar 31 Filed by: Frieberg Jacob B. -9.1%
3/26 Form 4 VACCINEX, INC. For: Mar 24 Filed by: FCMI Parent Co. -8.1%
1/27 Form SC 13D/A VACCINEX, INC. Filed by: FCMI Parent Co. -8.1%
10/19 Vaccinex Inc (NASDAQ: VCNX) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -7.7%
10/2 Form 4 VACCINEX, INC. For: Sep 30 Filed by: VACCINEX, INC. -7.2%
6/5 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.0%
11/9 Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) -11.1%
3/17 Vaccinex Inc (NASDAQ: VCNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.9%
3/23 Form 4 VACCINEX, INC. For: Mar 19 Filed by: FRIEDBERG ALBERT -9.4%
4/1 Form 4 VACCINEX, INC. For: Mar 31 Filed by: Frieberg Jacob B. -9.1%
3/26 Form 4 VACCINEX, INC. For: Mar 24 Filed by: FCMI Parent Co. -8.1%
1/27 Form SC 13D/A VACCINEX, INC. Filed by: FCMI Parent Co. -8.1%
10/19 Vaccinex Inc (NASDAQ: VCNX) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -7.7%
10/2 Form 4 VACCINEX, INC. For: Sep 30 Filed by: VACCINEX, INC. -7.2%
6/5 Vaccinex Inc (NASDAQ: VCNX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: